Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children

Summary

The purpose of the present study is to assess the immunogenicity and safety of vaccine GSK2321138A in children.

Timeline

Start

2009-10-08

Primary completion

2010-05-21

Completion

2010-05-21

Outcome

Met primary endpoint

paper Non-inferiority for shared strains and superiority for the alternate-lineage B strain unique to QIV was demonstrated for QIV versus TIV. PMID 25386965 ↗

Publications

• Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age. Pediatr Infect Dis J. 2014 Dec;33(12):1262-9. doi: 10.1097/INF.0000000000000463.

Drugs

Indications